Stem Cell Revolution

Can stem cells regenerate the human heart?There’s no one better to answer that question than Dr. Chuck Murry, one of the world’s leading physician-scientists in iPS research.In this episode, we sit down with Dr. Murry, the newly appointed Chair of the Department of Stem Cell Biology and Regenerative Medicine and Director of the Broad Center for Regenerative Medicine and Stem Cell Research at the Keck School of Medicine of USC. With decades of NIH-funded research, more than 200 scientific publications, and leadership roles spanning academia and biotech, Dr. Murry has dedicated his career to translating breakthrough science into real treatments—accessible to the patients who need them most.We explore:How stem cells can help repair damaged heart tissueWhat it takes to move therapies from lab to clinicWhy accessibility and scalability are key to lasting impactThe future of regenerative cardiology and translational medicineWhether you’re in clinical care, biotech, or just fascinated by the promise of stem cells, this conversation offers deep insight from one of the field’s most accomplished voices.🎧 Watch now to learn how science is changing the future of heart disease.Join the Conversation:Your feedback is crucial! Ask us anything in the comments about stem cell therapies and their regulation, or share your experiences.Don't forget to like, subscribe, and hit the bell icon for more updates on stem cell research and its revolutionary potential in healthcare. Links:HOPE STORE: https://www.hope.bio/merchWEBSITE - https://www.hope.bioINSTAGRAM - / hope.bioTWITTER - / hopebiosciencesFACEBOOK - / hopebiosciences#ChuckMurry #StemCells #HeartRegeneration #USCStemCell #TranslationalMedicine #CardiologyInnovation #RegenerativeMedicine #StemCellRevolution #BiomedicalInnovation

In this episode, we sit down with Dr. Anthony Luke, a nationally recognized expert in sports medicine, orthopedics, and regenerative therapies, to dive into the facts—and fiction—surrounding Platelet-Rich Plasma (PRP).Dr. Luke is a Professor in the Department of Orthopaedic Surgery and Director of the UCSF Human Performance Center. With decades of experience caring for Olympians, professional athletes, and everyday patients, he brings a clear, evidence-based perspective to one of the most popular (and misunderstood) treatments in regenerative medicine.We cover:What PRP actually isWhen it works—and when it doesn’tHow it compares to stem cells and other therapiesThe future of PRP in sports and musculoskeletal careWhether you're a provider, patient, or just curious about cutting-edge treatments, this conversation is packed with clinical insight and straight talk from a true expert.🎧 Watch now and get the clarity you’ve been looking for.Join the Conversation:Your feedback is crucial! Ask us anything in the comments about stem cell therapies and their regulation, or share your experiences.Don't forget to like, subscribe, and hit the bell icon for more updates on stem cell research and its revolutionary potential in healthcare. Links:HOPE STORE: https://www.hope.bio/merchWEBSITE - https://www.hope.bioINSTAGRAM - / hope.bioTWITTER - / hopebiosciencesFACEBOOK - / hopebiosciences

In this episode, we kick off our CTTACC 2025 podcast series with none other than Dr. Shibani Pati, a visionary leader in trauma and regenerative medicine and the driving force behind one of the field’s most impactful gatherings.Dr. Pati is Vice Chair and Professor of the Department of Laboratory Medicine, and Director of the Center for Translational Research in Transfusion Medicine and Cellular Therapies at UCSF. As a nationally recognized expert in vascular repair and trauma resuscitation, she has made CTTACC into a must-attend event for anyone working at the intersection of science, innovation, and patient impact.In just 8 minutes, you’ll hear how her vision brought together the brightest minds in the field—and why this conference is setting the tone for the future of cellular and regenerative medicine.🎧 Short, powerful, and the perfect place to start our CTTACC series.Join the Conversation:Your feedback is crucial! Ask us anything in the comments about stem cell therapies and their regulation, or share your experiences.Don't forget to like, subscribe, and hit the bell icon for more updates on stem cell research and its revolutionary potential in healthcare. Links:HOPE STORE: https://www.hope.bio/merchWEBSITE - https://www.hope.bioINSTAGRAM - / hope.bioTWITTER - / hopebiosciencesFACEBOOK - / hopebiosciences#StemCellRevolution #RegenerativeMedicine #FDA #StemCells #HCTP #Biologics #SystemicEffect #ScienceWithMagic

In this episode of Stem Cell Revolution, hosts Donna Chang and Jan Shultis take listeners on a journey into the final—and perhaps most complex—criteria of the FDA’s HCT/P framework: systemic effect and the metabolic activity of living cells. Inspired by a recent trip to Disney World, Donna returns with fresh perspective (and a little pixie dust) to explore how the magic of stem cell science often runs into the reality of regulation.While the idea of cells working throughout the body to repair and restore sounds like science fiction come true, the FDA sees it differently. When stem cell therapies have systemic effects or rely on living cells to function, they cross the line into biologic drug territory—bringing with them a world of regulatory hurdles.Through compelling case studies and deep scientific discussion, Donna and Jan break down what counts as a systemic effect, how metabolic activity is interpreted by the FDA, and why some therapies are exempt—like autologous use and reproductive applications. They also explore the gray areas of cytokine secretion, paracrine signaling, and what truly defines a “local” effect.From clinics that crossed the line and got flagged to industry calls for reform, this episode sheds light on where the field stands—and where it’s headed. Whether you’re a researcher, policymaker, or patient advocate, this episode offers a thoughtful, imaginative look at how we balance innovation with oversight in regenerative medicine.Join the Conversation:Your feedback is crucial! Ask us anything in the comments about stem cell therapies and their regulation, or share your experiences.Don't forget to like, subscribe, and hit the bell icon for more updates on stem cell research and its revolutionary potential in healthcare. Links:HOPE STORE: https://www.hope.bio/merchWEBSITE - https://www.hope.bioINSTAGRAM - / hope.bioTWITTER - / hopebiosciencesFACEBOOK - / hopebiosciences#StemCellRevolution #RegenerativeMedicine #FDA #StemCells #HCTP #Biologics #SystemicEffect #ScienceWithMagic

In this episode of Stem Cell Revolution, hosts Donna Chang and Jan Shultis tackle one of the most misunderstood—but critical—FDA rules governing regenerative medicine: the “No Combination” clause. What happens when you mix stem cells with something else? A scaffold, a growth factor, or even a drug may seem like a harmless addition—but that single tweak could change everything.Donna and Jan unpack the FDA’s criteria for HCT/Ps under 21 CFR 1271, focusing on the third rule: no combination with other articles unless specifically allowed. With real-world examples and regulatory case studies, they explore how even well-intentioned innovations can push a treatment out of the HCT/P category and straight into drug regulation territory.From protecting patient safety to preserving innovation, this episode explores the fine line between regulation and overreach—and what it means for the future of cell-based medicine.Join the Conversation:Your feedback is crucial! Ask us anything in the comments about stem cell therapies and their regulation, or share your experiences.Don't forget to like, subscribe, and hit the bell icon for more updates on stem cell research and its revolutionary potential in healthcare. Links:HOPE STORE: https://www.hope.bio/merchWEBSITE - https://www.hope.bioINSTAGRAM - / hope.bioTWITTER - / hopebiosciencesFACEBOOK - / hopebiosciences#StemCellRevolution #RegenerativeMedicine #StemCellTherapy #FDARegulations

We’re hitting pause on stem cell regulations to bring you a special report on Donna Chang’s latest trip to HHS! Who did she meet? What was discussed? And what happens when Hope arrives in our nation’s capital? Watch now to find out!

Join us as we decode the FDA's playbook on homologous use! In this episode, we dive into the critical differences between HCT/Ps and drugs, unravel real-world examples, and explore the regulatory drama that shapes regenerative medicine. Tune in to discover how a simple definition can redefine the future of cellular therapies!Join the Conversation:Your feedback is crucial! Ask us anything in the comments about stem cell therapies and their regulation, or share your experiences.Don't forget to like, subscribe, and hit the bell icon for more updates on stem cell research and its revolutionary potential in healthcare. Check out our website in the description below for more information or to order your exclusive "Not Plastic Bag" t-shirt!

Links:

HOPE STORE: https://www.hope.bio/merch

WEBSITE - https://www.hope.bio

INSTAGRAM - https://www.instagram.com/hope.bio/

TWITTER - https://twitter.com/hopebiosciences

FACEBOOK - https://www.facebook.com/hopebiosciences

#HopeBiosciences #StemCellResearch #YearInPhotos #Inspiration#StemCellRevolution #FDA #Regulation #MinimalManipulation #StemCellTherapy #2025

Join us for an insightful dive into the complex world of stem cell regulation in this episode of "Stem Cell Revolution." Recorded in early 2025, we explore the pivotal topic of minimal manipulation - a cornerstone in determining whether stem cell products are classified as drugs or human cell, tissue, or cellular and tissue-based products (HCT/Ps).

Stem Cells. Bank Them. Fleece Sweatshirt: https://www.hope.bio/product-page/stem-cells-bank-them-cropped-fleece-pullover

Join Donna Chang and Sherry Diers for a heartfelt and entertaining journey through Donna’s year in photos! In this episode, Donna opens up her camera roll to share the most meaningful, funny, and impactful moments of the past year.

In this episode of Stem Cell Revolution, hosts Donna Chang and Jan Shultis return after a brief hiatus with a powerful recap of recent events and achievements in the stem cell field. They discuss Hope Biosciences’ landmark gala event, where they successfully raised over $1 million to advance their foundation’s mission, touching on the importance of community support and the next generation’s role in this movement. The conversation then shifts to the recent clinical trial successes, including a groundbreaking multiple sclerosis study.